- 50% OFF
Dragon Pharma, Europe
LGD 4033
Oral · 15 mg · 100 tabs
$90.00
Compound ID
Ligandrol
Dosage
5–15 mg/day
Concentration
15 mg/tablet
Form
100 Tablets × 15 mg
Half-life
Approximately 24–36 hours
Properties
Shipping
Not available in this combination
Product overview
Dragon Pharma Ligandrol LGD-4033 15mg — Clinical-Grade SARM for Lean Mass Accretion & Strength Amplification
Dragon Pharma Ligandrol LGD-4033 15mg represents the cutting edge of selective androgen receptor modulation technology, engineered for athletes and physique competitors who demand substantial lean tissue development without the systemic burden of traditional anabolic steroids. As one of the most extensively researched SARMs in clinical literature, LGD-4033 demonstrates exceptional affinity for androgen receptors in skeletal muscle and bone, catalyzing pronounced hypertrophy and strength gains while circumventing many of the androgenic complications associated with conventional hormonal compounds. Dragon Pharma's precisely dosed 15mg tablets undergo rigorous independent verification, delivering a pharmaceutical-grade tool for individuals committed to measurable, high-quality muscular advancement.
What is Dragon Pharma LGD-4033?
LGD-4033, commonly referred to as Ligandrol, is a non-steroidal selective androgen receptor modulator (SARM) originally developed to address muscle wasting conditions and age-related sarcopenia. Unlike anabolic steroids, which indiscriminately activate androgen receptors across prostate, skin, scalp, and hepatic tissues, Ligandrol exhibits a markedly higher binding preference for receptors located within striated muscle and osseous matrix. This tissue selectivity underpins its favorable anabolic-to-androgenic ratio, enabling significant nitrogen retention, protein synthesis upregulation, and myogenic differentiation with substantially reduced risk of virilization, prostate enlargement, or dermatological disturbances. Dragon Pharma's 15mg oral formulation provides a convenient, accurately dosed delivery system that aligns with both clinical research parameters and advanced athletic protocols.
Key Benefits / Effects
- Accelerated Lean Hypertrophy: Users consistently report substantial dry mass accretion, typically ranging from 8–15 pounds per cycle, characterized by minimal subcutaneous water retention and high myofibrillar density.
- Explosive Strength Progression: Significant increases in compound lifts often manifest within the first fourteen days, enabling greater training volume and progressive overload capacity that further stimulates muscular adaptation.
- Enhanced Muscular Density: Ligandrol promotes a hard, three-dimensional aesthetic by increasing intramuscular contractile protein content rather than extracellular fluid accumulation, yielding a polished appearance even during caloric surplus phases.
- Osseous Matrix Reinforcement: Strong affinity for bone androgen receptors supports elevated bone mineral density, contributing to long-term skeletal resilience and reduced fracture risk under heavy axial loading.
- Catabolism Resistance: During hypocaloric cutting phases, LGD-4033 preserves existing lean tissue by maintaining anabolic signaling despite energy deficit, preventing the muscle degradation that typically accompanies aggressive fat loss.
- Favorable Androgenic Profile: Reduced interaction with scalp, sebaceous, and prostatic receptor populations minimizes hair loss, acne vulgaris, and benign prostatic hyperplasia risk relative to traditional androgens.
How Dragon Pharma LGD-4033 Works
Ligandrol functions through high-affinity binding to androgen receptors (AR) within skeletal myocytes and osteoblasts, initiating a conformational change that facilitates AR nuclear translocation and subsequent interaction with androgen response elements (AREs) on DNA. This genomic activation upregulates transcription of muscle-specific genes involved in protein synthesis, satellite cell proliferation, and myonuclear addition. Concurrently, LGD-4033 enhances nitrogen retention within muscle tissue, creating a sustained positive nitrogen balance essential for anabolism. The compound's selectivity arises from its differential coactivator recruitment profile and tissue-specific metabolic handling, which limit activation of androgenic pathways in non-target tissues. The net physiological result is robust hypertrophy, increased force production capacity, and improved bone turnover markers without the systemic androgenic load characteristic of testosterone derivatives.
Usage Information
Dragon Pharma LGD-4033 is supplied as 15mg oral tablets with a pharmacokinetic half-life of approximately 24–36 hours, supporting convenient once-daily administration. Novice users should initiate therapy at 5mg daily to evaluate individual response and tolerance. Intermediate practitioners typically employ 10mg daily, representing the most common effective dose for significant recomposition or bulking outcomes. Advanced users may escalate to 15–20mg daily, though higher ranges proportionally increase hypothalamic-pituitary-gonadal axis suppression and necessitate vigilant health monitoring. Standard cycle duration spans 8 weeks, extendable to 10–12 weeks for experienced users with comprehensive blood work oversight. Dosing may occur at any time of day, with or without food, though consistent daily timing optimizes steady-state plasma concentrations. Any cycle exceeding 6 weeks or utilizing doses above 5mg daily mandates a structured Post-Cycle Therapy (PCT) protocol to restore endogenous testosterone production.
Quality & Manufacturing
Dragon Pharma adheres to stringent analytical and manufacturing standards, with each Ligandrol batch subjected to independent third-party laboratory verification. Recent analytical testing confirmed an actual LGD-4033 content of 15.66mg per tablet—marginally overfilled to guarantee users receive the full stated 15mg dose. This level of dosing precision eliminates the uncertainty and underdosing endemic to the unregulated SARM marketplace, where products frequently contain negligible active ingredient or entirely different compounds. Such analytical transparency ensures that athletes can program their cycles with confidence, knowing each tablet delivers the exact pharmacological payload required for predictable hypertrophic and strength outcomes.
Possible Side Effects / Safety Information
- Endogenous Testosterone Suppression: LGD-4033 exerts dose-dependent negative feedback on the hypothalamic-pituitary-gonadal axis, reducing luteinizing hormone and follicle-stimulating hormone secretion. A structured PCT using Clomiphene or Tamoxifen is mandatory following cycles exceeding 6 weeks or 5mg daily.
- Lipid Profile Alteration: Reductions in high-density lipoprotein (HDL) cholesterol may occur, necessitating cardiovascular support through omega-3 supplementation, dietary fiber intake, and regular aerobic activity.
- Low Estrogen Manifestations: As circulating testosterone declines during suppression, downstream estrogen conversion decreases, potentially producing lethargy, diminished libido, and joint discomfort. A testosterone base may mitigate these symptoms during extended cycles.
- Mild Androgenic Expression: Although highly selective, genetically predisposed individuals at elevated doses may experience minor acne or accelerated androgenic alopecia.
- Hepatic Enzyme Elevation: While significantly less hepatotoxic than oral C17-alpha alkylated steroids, very high doses may produce slight transaminase elevations. Avoidance of alcohol and additional hepatotoxic agents is prudent during use.
Why Choose Dragon Pharma LGD-4033?
The unregulated SARM sector is saturated with counterfeit, mislabeled, and dangerously underdosed products that compromise both results and user safety. Dragon Pharma distinguishes itself through verified analytical transparency, with independent testing confirming 15.66mg potency per tablet. This precision enables athletes to design cycles with mathematical certainty rather than guesswork, ensuring that dosing protocols align with clinical research and real-world efficacy data. For individuals seeking a research-backed, tissue-selective anabolic agent capable of delivering substantial lean mass and strength without the systemic androgenic baggage of traditional steroids, Dragon Pharma Ligandrol represents a benchmark of quality and reliability.
Lab Report
Lab Report: 15.6 mg/tab
18 April 2025
15 mg/tab of label claim
| Analysis Date | 2025-04-18 |
| Lot / Batch ID | #HDLGD23 |
| Measured Potency | 15.6 mg/tab |
| Quality Assessment | Potency verified, purity passed, heavy metals passed. |
| Current Production Batch | Latest Batch |
Verify this result with your scratch-off code at the DPStore register.
Product FAQ
Questions, answered
LGD-4033 produces comparable lean mass gains to mild anabolic steroids but with significantly reduced androgenic side effects. Unlike testosterone or its derivatives, Ligandrol does not convert to estrogen or dihydrotestosterone, eliminating gynecomastia risk and minimizing hair loss or acne. However, it is generally less potent than heavy androgenic compounds and requires longer cycle durations to achieve maximal results.
For maximum hypertrophy, stack LGD-4033 with MK-677 (Ibutamoren) to amplify growth hormone secretion, appetite, and sleep-mediated recovery. Adding YK-11 as a myostatin inhibitor can further potentiate muscle size by removing the biological ceiling on hypertrophy. This combination creates a powerful anabolic environment supporting substantial dry mass accretion.
Absolutely. During caloric restriction, Ligandrol's potent anabolic signaling prevents muscle catabolism while supporting strength maintenance. Stacking with GW501516 (Cardarine) enhances endurance capacity and fatty acid oxidation, ensuring that weight loss originates primarily from adipose tissue rather than contractile muscle. The result is a harder, more defined physique with preserved training intensity.
Yes. Any cycle exceeding 6 weeks or utilizing doses above 5mg daily will suppress natural testosterone production to a degree requiring pharmaceutical recovery intervention. A standard PCT protocol consisting of Clomiphene Citrate (50/50/25/25mg) or Tamoxifen Citrate (40/40/20/20mg) over four weeks effectively restores endogenous hormone axis function and preserves cycle gains.
Most users report subjective improvements in training pumps, vascularity, and recovery within the first 7–10 days. Measurable strength increases typically appear by week two, while visible hypertrophic changes become pronounced between weeks 3 and 6. Full cycle results consolidate during the final weeks and can be preserved effectively with proper PCT and nutrition.
Ligandrol is characterized by notably dry gains with minimal extracellular fluid accumulation. Unlike aromatizing compounds that produce estrogen-mediated water retention, LGD-4033 increases myofibrillar protein content without significant subcutaneous bloating. This property makes it particularly valuable for athletes seeking a dense, hard aesthetic during both bulking and cutting phases.
Comprehensive metabolic panels should include total and free testosterone, luteinizing hormone, follicle-stimulating hormone, estradiol, lipid profiles (total cholesterol, HDL, LDL, triglycerides), and liver enzymes (ALT, AST). Baseline testing before cycle initiation, mid-cycle assessment at week 4–5, and post-PCT verification provide complete physiological oversight.
Protein intake should remain elevated at 1.0–1.2 grams per pound of body weight to support the increased protein synthesis demand. Progressive resistance training with adequate volume and intensity maximizes the compound's anabolic stimulus. Supplementation with omega-3 fatty acids supports cardiovascular health, while creatine monohydrate can synergistically amplify strength gains. Avoiding alcohol protects hepatic function and hormonal recovery capacity.
Due to its high selectivity and reduced androgenic activity, LGD-4033 is among the more female-friendly anabolic agents. Women typically respond well to significantly lower doses (2.5–5mg daily) and shorter cycle durations (6–8 weeks). Virilization risk remains low at conservative dosing, though individual sensitivity varies and discontinuation should occur immediately upon voice deepening or clitoral enlargement.
